Erythropoiesis-Stimulating Agent Use Among Non-Dialysis-Dependent CKD Patients Before and After the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Using a Large US Health Plan Database

TREAT appears to be a watershed study that was followed by a marked decline in ESA prescribing for patients with CKD.